GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
390.40
+11.85 (3.13%)
At close: Jun 27, 2025
179.84%
Market Cap 119.31B
Revenue (ttm) 61.15B
Net Income (ttm) 8.10B
Shares Out 318.47M
EPS (ttm) 25.43
PE Ratio 14.73
Forward PE n/a
Dividend 10.00 (2.62%)
Ex-Dividend Date Apr 18, 2025
Volume 397,292
Average Volume 359,559
Open 380.00
Previous Close 378.55
Day's Range 375.01 - 392.15
52-Week Range 125.60 - 481.00
Beta 0.38
RSI 55.26
Earnings Date Aug 22, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,700
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.

Financial Statements

News

There is no news available yet.